Orally Administered Diosgenin Alleviates Colitis in Mice Induced by Dextran Sulfate Sodium through Gut Microbiota Modulation and Short-Chain Fatty Acid Generation

He, Yaodong; Luo, Ruilin; Xia, Manying; Liu, Jiayu; Yao, Yanpeng; Min, Fenyi; Jin, Ruyi; Wang, Ruolin; Peng, Xiaoli

doi:10.1089/jmf.2021.k.0086

Cited by 8 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mucispirillum, similar to Akkermansia , colonizes the mucus layers associated with gut inflammation and has a special system to manage oxidative stress in colitis [ 35 , 59 ]. K. marxianus QHBYC4L2 significantly upregulates Mucispirillum abundance ( Figure 8 ), which is consistent with diosgenin-attenuated colitis caused by increasing Mucispirillum levels [ 60 ]. However, it has also been found that fructooligosaccharide alleviates gut inflammation and decreases Mucispirillum [ 39 ].…”

Section: Discussionsupporting

confidence: 68%

Anti-Inflammatory, Barrier Maintenance, and Gut Microbiome Modulation Effects of Saccharomyces cerevisiae QHNLD8L1 on DSS-Induced Ulcerative Colitis in Mice

Zhai

et al. 2023

IJMS

View full text Add to dashboard Cite

The use of probiotics has been considered as a new therapy option for ulcerative colitis (UC), and yeast has recently received widespread recommendation for human health. In this study, the probiotic characteristics of four yeast strains, Saccharomyces boulardii CNCMI-745, Kluyveromyces marxianus QHBYC4L2, Saccharomyces cerevisiae QHNLD8L1, and Debaryomyces hansenii QSCLS6L3, were evaluated in vitro; their ability to ameliorate dextran sulfate sodium (DSS)-induced colitis was investigated. Among these, S. cerevisiae QHNLD8L1 protected against colitis, which was reflected by increased body weight, colon length, histological injury relief, decreased gut inflammation markers, and intestinal barrier restoration. The abundance of the pathogenic bacteria Escherichia–Shigella and Enterococcaceae in mice with colitis decreased after S. cerevisiae QHNLD8L1 treatment. Moreover, S. cerevisiae QHNLD8L1 enriched beneficial bacteria Lactobacillus, Faecalibaculum, and Butyricimonas, enhanced carbon metabolism and fatty acid biosynthesis function, and increased short chain fatty acid (SCFAs) production. Taken together, our results indicate the great potential of S. cerevisiae QHNLD8L1 supplementation for the prevention and alleviation of UC.

show abstract

Section: Discussionsupporting

confidence: 68%

Anti-Inflammatory, Barrier Maintenance, and Gut Microbiome Modulation Effects of Saccharomyces cerevisiae QHNLD8L1 on DSS-Induced Ulcerative Colitis in Mice

Zhai

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…13,15 Recent studies also demonstrate that diosgenin ameliorates dextran sulfate sodium (DSS)-induced colitis in mice through the modulation of gut microbiota and the enhancement of SCFA production. 28 Compared with DSS-induced colon injury, diosgenin improved the colon homeostasis through modulating the gut microbiota, including increases in the relative abundance of several probiotic bacteria, and decreases in the pathogenic bacteria. 28 The present study also found that diosgenin protects against elevated blood pressure and cardiac hypertrophy in SHR.…”

Section: Discussionmentioning

confidence: 99%

“…28 Compared with DSS-induced colon injury, diosgenin improved the colon homeostasis through modulating the gut microbiota, including increases in the relative abundance of several probiotic bacteria, and decreases in the pathogenic bacteria. 28 The present study also found that diosgenin protects against elevated blood pressure and cardiac hypertrophy in SHR. Moreover, a modified gut microbiota composition and ameliorated intestinal pathology and homeostasis were observed in diosgenin-treated SHR.…”

Section: Discussionmentioning

confidence: 99%

Diosgenin exerts an antihypertensive effect in spontaneously hypertensive rats via gut–brain communication

Peng

Bai

et al. 2022

Food Funct.

View full text Add to dashboard Cite

show abstract

The microbiota-gut-brain axis: a potential target in the small-molecule compounds and gene therapeutic strategies for Parkinson’s disease

Jiao,

Zhou,

2024

Neurol Sci

View full text Add to dashboard Cite

Backgrounds Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by motor symptoms and non-motor symptoms. It has been found that intestinal issues usually precede motor symptoms. Microorganisms in the gastrointestinal tract can affect central nervous system through the microbiota-gut-brain axis. Accumulating evidence has shown that disturbances in the microbiota-gut-brain axis are linked with PD. Thus, this pathway appears to be a promising therapeutic target for treatment of PD. Objectives In this review, we mainly described gut dysbiosis in PD and their underlying mechanisms for mediating neuroinflammation and peripheral immune response in PD pathology and futher discussed the potential small-molecule compounds and genic therapeutic strategies targeting the microbiota-gut-brain axis and their applications in PD. Conclusions Studies have found that some small molecule compounds and alterations of inflammation-related genes can improve the motor and non-motor symptoms of PD by improving the microbiota-gut-brain axis, which may provide potentially beneficial drugs and molecular targets for the therapies of PD.

show abstract

Orally Administered Diosgenin Alleviates Colitis in Mice Induced by Dextran Sulfate Sodium through Gut Microbiota Modulation and Short-Chain Fatty Acid Generation

Cited by 8 publications

References 43 publications

Anti-Inflammatory, Barrier Maintenance, and Gut Microbiome Modulation Effects of Saccharomyces cerevisiae QHNLD8L1 on DSS-Induced Ulcerative Colitis in Mice

Anti-Inflammatory, Barrier Maintenance, and Gut Microbiome Modulation Effects of Saccharomyces cerevisiae QHNLD8L1 on DSS-Induced Ulcerative Colitis in Mice

Diosgenin exerts an antihypertensive effect in spontaneously hypertensive rats via gut–brain communication

The microbiota-gut-brain axis: a potential target in the small-molecule compounds and gene therapeutic strategies for Parkinson’s disease

Contact Info

Product

Resources

About